Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 23, 2026Journal of Lipid and AtherosclerosisOpen Access

Fimasartan plus moderate statins linked to ~74% target BP control and high LDL-C goal attainment.

View Full Paper
Ask AI
Bookmark
Share

Why the study?

The study aimed to evaluate the real-world efficacy and safety of combining fimasartan 30 mg with moderate-intensity statins in patients with hypertension and dyslipidemia.

Does a combination of fimasartan 30 mg and moderate-intensity statins improve blood pressure and LDL-C control in patients with hypertension and dyslipidemia?

Population

5,264 patients with hypertension and dyslipidemia

Comparison

Combination of fimasartan 30 mg and moderate-intensity statins

Design

Multicenter prospective non-interventional observational study

Follow-up

12 weeks

Key result

A combination of fimasartan 30 mg and moderate-intensity statins resulted in 74.4% of patients achieving target blood pressure and 85.6% achieving target LDL-C levels at 12 weeks.

Authors

KCK. ChoSKS H KimSLSang Rok Lee

Discussion

Loading...

Member takes

Overview

May support dual BP and LDL-C control with fimasartan plus statins in real-world cohorts; leaves open randomized confirmation.

Key Points

  • Investigate the efficacy and safety of fimasartan and statins in patients with hypertension and dyslipidemia.
  • Non-interventional, multicenter, prospective observational study
  • Included 5,264 patients with 12-week follow-up
  • Efficacy outcomes were target blood pressure (BP) and LDL-C control.
  • 74.4% achieved target BP (95% CI, 73.2-75.5)
  • 85.6% achieved LDL-C control (95% CI, 84.5-86.8)
  • 65.6% achieved simultaneous control of both BP and LDL-C (95% CI, 64.1-67.2).

Study Design

Type

Observational (n=5,264)

Multicenter

Yes

Structured PICO

Does a combination of fimasartan 30 mg and moderate-intensity statins improve blood pressure and LDL-C control in patients with hypertension and dyslipidemia?

P
Population
5,264 patients with hypertension and dyslipidemia, median age 63, 50% female, enrolled from 401 primary clinics, 6 secondary hospitals, and 18 tertiary care hospitals in Korea.
I
Intervention
Combination of fimasartan 30 mg and moderate-intensity statins (rosuvastatin 5 or 10 mg, or atorvastatin 10 or 20 mg, with or without amlodipine 5 mg) taken as single pills for 12 weeks.
O
Outcome
Co-primary efficacy outcomes: percentage of patients that achieved target blood pressure (BP) and low-density lipoprotein cholesterol (LDL-C) control at 12 weeks.surrogate

A combination of fimasartan 30 mg and moderate-intensity statins effectively and safely controls both blood pressure and LDL-C in a real-world hypertensive and dyslipidemic population.

Limitations

  • Performed in Korea, limiting generalizability to other ethnicities
  • Inherent biases including selection or residual confounding due to observational design
  • Lack of details on why very high-risk patients were treated only with moderate-intensity statins
  • Short duration of 12-week follow-up
  • Lifestyle interventions (diet, exercise, weight control) were not included in the study

Cite This Study

Cho et al. (2026) conducted an observational in Hypertension and dyslipidemia (n=5,264). Fimasartan and moderate-intensity statins was evaluated on Percentage of patients achieving target blood pressure (BP) control at 12 weeks (95% CI 73.2-75.5). A combination of fimasartan 30 mg and moderate-intensity statins resulted in 74.4% of patients achieving target blood pressure and 85.6% achieving target LDL-C levels at 12 weeks.

synapsesocial.com/papers/6a11439848a409a3a49de60ehttps://doi.org/10.12997/jla.2026.15.2.361
View Full Paper
Ask AI
Bookmark
Share